|
|
|
|
| LEADER |
07380nma a2202041 u 4500 |
| 001 |
EB001974563 |
| 003 |
EBX01000000000000001137465 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783039285389
|
| 020 |
|
|
|a books978-3-03928-539-6
|
| 020 |
|
|
|a 9783039285396
|
| 100 |
1 |
|
|a Koch, Benjamin
|
| 245 |
0 |
0 |
|a Kidney Inflammation, Injury and Regeneration
|h Elektronische Ressource
|
| 260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (496 p.)
|
| 653 |
|
|
|a arachidonic acid
|
| 653 |
|
|
|a diabetic kidney disease
|
| 653 |
|
|
|a myofibroblast
|
| 653 |
|
|
|a cAMP Regulatory Element Binding Protein (CREB)
|
| 653 |
|
|
|a chronic kidney disease (CKD)
|
| 653 |
|
|
|a conditioned medium
|
| 653 |
|
|
|a kidney injury
|
| 653 |
|
|
|a genotype
|
| 653 |
|
|
|a cyclooxygenase
|
| 653 |
|
|
|a haem
|
| 653 |
|
|
|a type I collagen
|
| 653 |
|
|
|a regulated necrosis
|
| 653 |
|
|
|a tubular injury
|
| 653 |
|
|
|a glomerular filtration barrier (GFB)
|
| 653 |
|
|
|a signaling cascade
|
| 653 |
|
|
|a CmklR1
|
| 653 |
|
|
|a chronic kidney injury
|
| 653 |
|
|
|a modified-MSCs
|
| 653 |
|
|
|a Farnesiferol B
|
| 653 |
|
|
|a inflammatory bowel disease (IBD)
|
| 653 |
|
|
|a polyunsaturated fatty acids
|
| 653 |
|
|
|a niches
|
| 653 |
|
|
|a podocyte
|
| 653 |
|
|
|a scattered tubular cells
|
| 653 |
|
|
|a endotoxemia
|
| 653 |
|
|
|a xanthine oxidase
|
| 653 |
|
|
|a obese kidney fibrosis
|
| 653 |
|
|
|a Taiwan
|
| 653 |
|
|
|a hypertension
|
| 653 |
|
|
|a diabetes mellitus
|
| 653 |
|
|
|a focal segmental glomerulosclerosis
|
| 653 |
|
|
|a Class IIa Histone Deacetylases (HDAC)
|
| 653 |
|
|
|a acute kidney failure
|
| 653 |
|
|
|a glomerular damage
|
| 653 |
|
|
|a noninvasive
|
| 653 |
|
|
|a chronic kidney disease
|
| 653 |
|
|
|a cytochrome P450
|
| 653 |
|
|
|a prediction
|
| 653 |
|
|
|a lncRNA
|
| 653 |
|
|
|a kidney proximal tubule
|
| 653 |
|
|
|a SGLT2 inhibitors
|
| 653 |
|
|
|a renal cell carcinoma
|
| 653 |
|
|
|a renal progenitors
|
| 653 |
|
|
|a long non-coding RNA
|
| 653 |
|
|
|a chemerin
|
| 653 |
|
|
|a mesodermal stem cell
|
| 653 |
|
|
|a interleukin-6
|
| 653 |
|
|
|a molecular mechanisms
|
| 653 |
|
|
|a alport syndrome
|
| 653 |
|
|
|a polymorphism
|
| 653 |
|
|
|a rhabdomyolysis
|
| 653 |
|
|
|a polyploidization
|
| 653 |
|
|
|a renal stem cells
|
| 653 |
|
|
|a pigment nephropathy
|
| 653 |
|
|
|a slit diaphragm
|
| 653 |
|
|
|a cytotoxicity
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a microRNA
|
| 653 |
|
|
|a glomerular injury
|
| 653 |
|
|
|a stem cell
|
| 653 |
|
|
|a hematuria
|
| 653 |
|
|
|a kidney transplantation
|
| 653 |
|
|
|a lipoxygenase
|
| 653 |
|
|
|a non-coding RNAs
|
| 653 |
|
|
|a empagliflozin
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a podocin
|
| 653 |
|
|
|a inflammatory maker
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a mesenchymal stem cells
|
| 653 |
|
|
|a natural products
|
| 653 |
|
|
|a renovascular hypertension
|
| 653 |
|
|
|a proximal tubule
|
| 653 |
|
|
|a exosomes
|
| 653 |
|
|
|a transcription
|
| 653 |
|
|
|a renal tubular cells
|
| 653 |
|
|
|a DSS-colitis
|
| 653 |
|
|
|a Salt Inducible Kinase (SIK)
|
| 653 |
|
|
|a acute and chronic kidney disease
|
| 653 |
|
|
|a type IV collagen
|
| 653 |
|
|
|a diagnostics
|
| 653 |
|
|
|a mesenchymal stromal cells
|
| 653 |
|
|
|a renal injury
|
| 653 |
|
|
|a G-protein-coupled bile acid receptor (TGR5)
|
| 653 |
|
|
|a injury
|
| 653 |
|
|
|a NLRP3 inflammasome
|
| 653 |
|
|
|a renal fibrosis
|
| 653 |
|
|
|a allograft rejection
|
| 653 |
|
|
|a modifier gene
|
| 653 |
|
|
|a ROS
|
| 653 |
|
|
|a microRNAs
|
| 653 |
|
|
|a renal ischemia-reperfusion
|
| 653 |
|
|
|a omega-3 fatty acid
|
| 653 |
|
|
|a diabetic kidney diseases
|
| 653 |
|
|
|a CXCL13
|
| 653 |
|
|
|a fibrosis
|
| 653 |
|
|
|a nephrin
|
| 653 |
|
|
|a long non-coding RNAs
|
| 653 |
|
|
|a B-cell attracting chemokine
|
| 653 |
|
|
|a dapagliflozin
|
| 653 |
|
|
|a T cell-mediated rejection
|
| 653 |
|
|
|a apoptosis
|
| 653 |
|
|
|a 2-kidney-1-clip
|
| 653 |
|
|
|a C-reactive protein
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a KIT assay
|
| 653 |
|
|
|a exosome
|
| 653 |
|
|
|a diabetic nephropathy
|
| 653 |
|
|
|a ischemia-reperfusion
|
| 653 |
|
|
|a renal inflammation
|
| 653 |
|
|
|a therapeutic target
|
| 653 |
|
|
|a papilla
|
| 653 |
|
|
|a pericyte
|
| 653 |
|
|
|a extracellular vesicles
|
| 653 |
|
|
|a kidney
|
| 653 |
|
|
|a kidney inflammation
|
| 653 |
|
|
|a necrosis
|
| 653 |
|
|
|a molecular signaling
|
| 653 |
|
|
|a mesenchymal stem cell
|
| 653 |
|
|
|a CREB Regulated Transcriptional Coactivators (CRTC)
|
| 653 |
|
|
|a lysophosphatidic acid receptor
|
| 653 |
|
|
|a endotoxemia-induced oliguric kidney injury
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a AKI
|
| 653 |
|
|
|a Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-?B)
|
| 653 |
|
|
|a Thy1.1 nephritis
|
| 653 |
|
|
|a glomerular basement membrane
|
| 653 |
|
|
|a miRNA
|
| 653 |
|
|
|a type V collagen
|
| 653 |
|
|
|a therapeutics targets
|
| 653 |
|
|
|a acute kidney injury
|
| 653 |
|
|
|a KIT-IgA score
|
| 653 |
|
|
|a LPS-binding protein
|
| 653 |
|
|
|a 2k1c
|
| 653 |
|
|
|a epithelial cells
|
| 653 |
|
|
|a signal transduction
|
| 653 |
|
|
|a GLP-1 receptor agonists
|
| 653 |
|
|
|a IgA nephropathy
|
| 653 |
|
|
|a glomerulus
|
| 653 |
|
|
|a ischemia/reperfusion injury
|
| 653 |
|
|
|a differentiation
|
| 653 |
|
|
|a cPLA2 and COX-2
|
| 653 |
|
|
|a IL-18
|
| 653 |
|
|
|a lysophosphatidic acid
|
| 700 |
1 |
|
|a Geiger, Helmut
|
| 700 |
1 |
|
|a Baer, Patrick C.
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-03928-539-6
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/51086
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2165
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 333
|
| 082 |
0 |
|
|a 580
|
| 520 |
|
|
|a Acute kidney injury (AKI) is still associated with high morbidity and mortality incidence rates, and also bears an elevated risk of subsequent chronic kidney disease. Although the kidney has a remarkable capacity for regeneration after injury and may recover completely depending on the type of renal lesions, the options for clinical intervention are restricted to fluid management and extracorporeal kidney support. The development of novel therapies to prevent AKI, to improve renal regeneration capacity after AKI, and to preserve renal function is urgently needed. The Special Issue covers research articles that investigated the molecular mechanisms of inflammation and injury during different renal pathologies, renal regeneration, diagnostics using new biomarkers, and the effects of different stimuli like medication or bacterial components on isolated renal cells or in vivo models. The Special Issue contains important reviews that consider the current knowledge of cell death and regeneration, inflammation, and the molecular mechanisms of kidney diseases. In addition, the potential of cell-based therapy approaches that use mesenchymal stromal/stem cells or their derivates is summarized. This edition is complemented by reviews that deal with the current data situation on other specific topics like diabetes and diabetic nephropathy or new therapeutic targets.
|